Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
ROIV
Roivant Sciences Ltd.
Mosliciguat is an inhaled sGC activator for PH-ILD, aligning with Cardiovascular Drugs.
|
$20.75B |
$29.80
+2.11%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$19.88B |
$104.93
+0.02%
|
|
WST
West Pharmaceutical Services, Inc.
West generates revenue from contract manufacturing services, moving towards higher-margin opportunities.
|
$19.69B |
$273.73
+1.45%
|
|
IFF
International Flavors & Fragrances Inc.
DEB and enzyme-based biotechnologies are core to IFF's Health & Biosciences innovation and product offerings.
|
$19.43B |
$75.87
+5.29%
|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$19.20B |
$97.81
+2.61%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$18.72B |
$25.14
+2.97%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$18.33B |
$28.54
+0.85%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$16.91B |
$14.68
+4.75%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$14.94B |
$244.53
+0.65%
|
|
BBIO
BridgeBio Pharma, Inc.
Attruby (acoramidis) and other BridgeBio pipeline assets are oral small-molecule therapeutics, covering multiple rare genetic diseases.
|
$14.79B |
$76.69
-1.06%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$14.66B |
$520.52
+0.94%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$14.33B |
$203.62
+1.07%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$14.18B |
$28.77
-5.89%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.29B |
$133.24
+3.76%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$12.36B |
$203.41
+2.82%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.26B |
$75.72
+0.61%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$12.08B |
$531.77
+1.34%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$12.04B |
$44.90
+1.16%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.77B |
$23.69
+2.42%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$11.39B |
$90.31
+5.38%
|
|
RDY
Dr. Reddy's Laboratories Limited
Core business focused on manufacturing and selling generic drugs.
|
$11.10B |
$13.29
+1.80%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.50B |
$54.65
+1.01%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$10.44B |
$66.78
+4.00%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$9.62B |
$18.71
+3.17%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$9.53B |
$189.08
+2.65%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$9.44B |
$69.62
+2.42%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$9.31B |
$119.58
+3.46%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$9.23B |
$59.24
+3.29%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$9.05B |
$184.01
+4.00%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$8.98B |
$41.23
+0.65%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$8.76B |
$120.15
-1.89%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.57B |
$130.68
+1.86%
|
|
PRAX
Praxis Precision Medicines, Inc.
Pipeline includes rare-disease CNS DEEs (SCN2A/SCN8A), aligning with Rare Diseases.
|
$8.56B |
$343.00
+7.06%
|
Showing page 3 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
